CD274 and neoplasm: Potential biomarkers include high PDL1 expression for anti-PD1/PDL1 therapies, and high tumor mutational burden (TMB), both now approved by the United States Food and Drug Administration (FDA) as an indication for using immunotherapy unrelated to diagnosis [2].